Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Digoxin in hyperthyroidism

D H Huffman, C D Klaassen, C R Hartman

    Clinical Pharmacology and Therapeutics
    |November 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Hyperthyroidism reduces the effectiveness of digoxin, a heart medication, by decreasing its absorption and increasing its excretion. This necessitates higher doses for patients with atrial fibrillation to achieve therapeutic effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Degradation of Keap1 activates BH3-only proteins Bim and PUMA during hepatocyte lipoapoptosis.

    Cell death and differentiation·2014
    Same author

    Polychlorinated biphenyl congeners that increase the glucuronidation and biliary excretion of thyroxine are distinct from the congeners that enhance the serum disappearance of thyroxine.

    Drug metabolism and disposition: the biological fate of chemicals·2011
    Same author

    Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation.

    Journal of pharmacokinetics and biopharmaceutics·2010
    Same author

    Application of multivariate statistical procedures to identify transcription factors that correlate with MRP2, 3, and 4 mRNA in adult human livers.

    Xenobiotica; the fate of foreign compounds in biological systems·2009
    Same author

    Induction of rat UDP-glucuronosyltransferases in liver and duodenum by microsomal enzyme inducers that activate various transcriptional pathways.

    Drug metabolism and disposition: the biological fate of chemicals·2006
    Same author

    Alterations in transporter expression in liver, kidney, and duodenum after targeted disruption of the transcription factor HNF1alpha.

    Biochemical pharmacology·2006
    Same journal

    Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Reply to: "The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient".

    Clinical pharmacology and therapeutics·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Endocrinology
    • Cardiology

    Background:

    • Digoxin is a crucial medication for managing atrial fibrillation and heart failure.
    • Thyroid hormone levels significantly influence drug metabolism and elimination.
    • Understanding digoxin pharmacokinetics in altered thyroid states is essential for effective patient care.

    Observation:

    • A patient with chronic atrial fibrillation and newly developed hyperthyroidism required escalating digoxin doses for adequate ventricular rate control.
    • This patient exhibited decreased systemic availability of oral digoxin.
    • Hyperthyroid rats showed significantly lower plasma digoxin concentrations compared to controls.

    Findings:

    • Digoxin metabolism and excretion are altered in hyperthyroidism.

    Related Experiment Videos

  • A threefold increase in biliary digoxin excretion was observed in hyperthyroid rats, correlating with reduced plasma concentrations.
  • Hypothyroid rats demonstrated reduced biliary digoxin excretion compared to both control and hyperthyroid groups.

    • Implications:

    • Altered digoxin absorption and increased biliary excretion contribute to its diminished therapeutic effect in hyperthyroidism.
    • Dosage adjustments for digoxin may be necessary in patients with hyperthyroidism to maintain therapeutic efficacy.
    • These findings highlight the importance of considering thyroid status in digoxin therapy management.